# Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells

> **NCT00458679** · PHASE1 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 6 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia (CLL)

## Interventions

- **BIOLOGICAL:** CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE

## Key facts

- **NCT ID:** NCT00458679
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-10
- **Final completion:** 2013-08
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2014-02-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00458679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00458679, "Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00458679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*